par Van Schil, Paul;Berzenji, Lawek;Desmet, Agnès 
;Van Houtte, Paul
Référence Revue des Maladies Respiratoires Actualites, 14, 2, page (2S146-2S150)
Publication Publié, 2022-10
;Van Houtte, Paul Référence Revue des Maladies Respiratoires Actualites, 14, 2, page (2S146-2S150)
Publication Publié, 2022-10
Article révisé par les pairs
| Résumé : | Although its definition has not been clearly established, oligometastatic disease is now recognized as a specific entity in patients with a limited number of metastases. Its treatment remains a highly controversial topic with treatment options ranging from conservative therapy to more aggressive modalities with the principal aim to control the primary tumour and distant metastatic sites. There is a clear relationship with the current progress in systemic therapies including targeted therapies and immunotherapy, but also specific advances in surgical and radiation techniques. Most available data come from retrospective studies with their inherent bias but several smaller randomised trials have recently been published. Precise patient selection for such an aggressive treatment remains a major challenge. There is a risk of overtreatment with its associated complications and reduction of quality of life. On the other hand, long-term survival has been described in a well-selected population. 1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved. |
